AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16696804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG 18 x 10(9) viable bacteria/day
Number of subjects: 187
Study 16696804 — intervention group
Group type: COMPARATOR
Intervention: mesalazine 2400 mg/day
Number of subjects: 187
Study 16696804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG + mesalazine
Number of subjects: 187
Study 16696804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 187
Study 14970966 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP), averaging 4.5+/‐1.5 training sessions, each 30 minutes long.
Number of subjects: 35
Study 14970966 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program (control group).
Number of subjects: 35
Study 11739977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated classification algorithm using dual-gate TCD and wavelet representation
Number of subjects: 600
Study 11739977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated classification algorithm for distinguishing solid from gaseous emboli
Number of subjects: 600
Study 9118709 — intervention group
Group type: EXPERIMENTAL
Intervention: HMEF (Hygroster; DAR; Mirandola, Italy)
Number of subjects: 115
Study 9118709 — intervention group
Group type: COMPARATOR
Intervention: Water-bath humidifier heated at 32 degrees C (HWBH)
Number of subjects: 115
Study 8437031 — intervention group
Group type: EXPERIMENTAL
Intervention: PASE by mail
Number of subjects: 0
Study 8437031 — intervention group
Group type: EXPERIMENTAL
Intervention: PASE by telephone
Number of subjects: 0
Study 8437031 — intervention group
Group type: EXPERIMENTAL
Intervention: PASE scores
Number of subjects: 0
Study 3741936 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenol
Number of subjects: 0
Study 3741936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29117012 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 100
Study 29117012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26764319 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual bread-based lunch (UBL)
Number of subjects: 750
Study 26764319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot lunch meal (HLM)
Number of subjects: 750
Study 26764319 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total ARs
Number of subjects: 750
Study 26764319 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported WG intake
Number of subjects: 750
Study 26764319 — intervention group
Group type: EXPERIMENTAL
Intervention: AR C17:0 homolog
Number of subjects: 750
Study 24727258 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 2397
Study 24727258 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 2397
Study 24727258 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2397
Study 21737565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 206
Study 20416554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse
Number of subjects: 160
Study 20416554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐EZ
Number of subjects: 160
Study 20416554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec Plus
Number of subjects: 160
Study 20416554 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 20416554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐EZ/XP Bond
Number of subjects: 160
Study 20416554 — intervention group
Group type: COMPARATOR
Intervention: Control/AdheSE
Number of subjects: 160
Study 18565598 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment (ear drops and saline solution)
Number of subjects: 50
Study 18565598 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with systemic antibiotics
Number of subjects: 50
Study 16335787 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic pearls (GP) 250 mg per day for 2 months
Number of subjects: 20
Study 16335787 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 20
Study 12464091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐OP) at 40 ng kg‐1 h‐1
Number of subjects: 8
Study 12464091 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 12464091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐OP) at 5 or 20 ng kg‐1 h‐1
Number of subjects: 8
Study 12464091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐OP)
Number of subjects: 8
Study 10505732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate enemas (20 g/100 ml)
Number of subjects: 60
Study 10505732 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone enemas (20 mg/100 ml)
Number of subjects: 60
Study 8525039 — intervention group
Group type: EXPERIMENTAL
Intervention: Active labor management (study group, n = 75)
Number of subjects: 145
Study 8525039 — intervention group
Group type: COMPARATOR
Intervention: Traditional labor management (control group, n = 70)
Number of subjects: 145
Study 2302053 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank ergometer (ACE) exercise
Number of subjects: 9
Study 2302053 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair ergometer (WCE) exercise
Number of subjects: 9
Study 7447412 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 54
Study 7447412 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 54
Study 7447412 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin and Cloxacillin (combined data)
Number of subjects: 54
Study 6581065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol powder for inhalation
Number of subjects: 20
Study 6581065 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol spray
Number of subjects: 20
Study 31058628 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta-percha/AH Plus
Number of subjects: 60
Study 31058628 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 60
Study 31058628 — intervention group
Group type: COMPARATOR
Intervention: Control Group II (not specified)
Number of subjects: 60
Study 31058628 — intervention group
Group type: COMPARATOR
Intervention: Control Group IV (not specified)
Number of subjects: 60
Study 29290053 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 26
Study 29290053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 27681016 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental brushes used daily with a standard manual toothbrush twice daily
Number of subjects: 46
Study 27681016 — intervention group
Group type: COMPARATOR
Intervention: Standard manual toothbrush
Number of subjects: 46
Study 27681016 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental brushes
Number of subjects: 46
Study 27681016 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline bleeding frequency
Number of subjects: 46
Study 25503280 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week aerobic training program (running and rope skipping)
Number of subjects: 30
Study 25503280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 22460297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 22460297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20207952 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 601
Study 20207952 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 601
Study 20207952 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 and/or BCRP variant genotypes
Number of subjects: 601
Study 20207952 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9, CYP2C19, or SLCO1B1 variants
Number of subjects: 601
Study 20207952 — intervention group
Group type: EXPERIMENTAL
Intervention: Most common genotypes for CYP3A5 and BCRP
Number of subjects: 601
Study 17507702 — intervention group
Group type: COMPARATOR
Intervention: Continued fluticasone (100 microg twice daily)
Number of subjects: 500
Study 17507702 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (100 microg) plus salmeterol (50 microg) each night
Number of subjects: 500
Study 17507702 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg each night)
Number of subjects: 500
Study 15654254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial adipose tissue measurement using cardiac CT scans
Number of subjects: 80
Study 12073204 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet pheresis
Number of subjects: 54
Study 12073204 — intervention group
Group type: COMPARATOR
Intervention: Control (no platelet pheresis)
Number of subjects: 54
Study 11552615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (10 procedures)
Number of subjects: 64
Study 11552615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonophoresis treatment (diclofenac gel, 10 procedures)
Number of subjects: 64
Study 7768254 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril orally
Number of subjects: 12
Study 7768254 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril intravenously
Number of subjects: 12
Study 7768254 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ramiprilat intravenously
Number of subjects: 12
Study 2283645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60-180 mg twice daily)
Number of subjects: 48
Study 2283645 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25-75 mg twice daily)
Number of subjects: 48
Study 465123 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 11
Study 31530665 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 514
Study 31530665 — intervention group
Group type: COMPARATOR
Intervention: continued GLP-1 RA therapy
Number of subjects: 514
Study 29978268 — intervention group
Group type: EXPERIMENTAL
Intervention: 940-nm diode laser treatment after undisplaced flap surgery
Number of subjects: 30
Study 29978268 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery without laser treatment)
Number of subjects: 30
Study 26429974 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue ACEi, ARB or combination of both (experimental arm)
Number of subjects: 410
Study 26429974 — intervention group
Group type: COMPARATOR
Intervention: Continue ACEi, ARB or combination of both (control arm)
Number of subjects: 410
Study 23957716 — intervention group
Group type: EXPERIMENTAL
Intervention: AC + AET (doxorubicin plus cyclophosphamide with aerobic training)
Number of subjects: 20
Study 23957716 — intervention group
Group type: COMPARATOR
Intervention: AC (doxorubicin plus cyclophosphamide)
Number of subjects: 20
Study 23957716 — intervention group
Group type: EXPERIMENTAL
Intervention: AC + AET
Number of subjects: 20
Study 23957716 — intervention group
Group type: COMPARATOR
Intervention: AC
Number of subjects: 20
Study 22318559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed pushing speed (FPS) at 80-100% maximal speed
Number of subjects: 20
Study 22318559 — intervention group
Group type: COMPARATOR
Intervention: Self-selected pushing speed (SPS)
Number of subjects: 20
Study 19550210 — intervention group
Group type: EXPERIMENTAL
Intervention: Online colposcopic image assessment
Number of subjects: 919
Study 19550210 — intervention group
Group type: EXPERIMENTAL
Intervention: Online colpophotographic assessment of high-grade disease
Number of subjects: 919
Study 19550210 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade diagnosis by Reid Index scoring
Number of subjects: 919
Study 19550210 — intervention group
Group type: COMPARATOR
Intervention: Same-day enrollment colposcopy
Number of subjects: 919
Study 17472819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 15 microg BID
Number of subjects: 717
Study 17472819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 25 microg BID
Number of subjects: 717
Study 17472819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 50 microg QD
Number of subjects: 717
Study 17472819 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg BID
Number of subjects: 717
Study 17472819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 14643168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (75 mg twice daily)
Number of subjects: 242
Study 14643168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 14643168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (75 mg twice daily) in patients with more severe symptoms
Number of subjects: 242
Study 14643168 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with more severe symptoms
Number of subjects: 242
Study 11739832 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U botulinum toxin type A
Number of subjects: 24
Study 11739832 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin type A
Number of subjects: 24
Study 9003220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine casein
Number of subjects: 0
Study 9003220 — intervention group
Group type: COMPARATOR
Intervention: House dust mite antigens
Number of subjects: 0
Study 8492965 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methotrexate (7500 mg/m2)
Number of subjects: 23
Study 8492965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (750 mg/m2)
Number of subjects: 23
Study 8492965 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 3498356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 148
Study 3498356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 28931055 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia for 72 hours
Number of subjects: 75
Study 28931055 — intervention group
Group type: COMPARATOR
Intervention: Normothermic treatment
Number of subjects: 75
Study 25908089 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus best medical treatment
Number of subjects: 115
Study 25908089 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 115
Study 23427864 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 453
Study 23427864 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 453
Study 23427864 — intervention group
Group type: COMPARATOR
Intervention: metformin monotherapy
Number of subjects: 453
Study 23427864 — intervention group
Group type: COMPARATOR
Intervention: metformin+pioglitazone combination
Number of subjects: 453
Study 21295767 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT‐based skills training (n=26)
Number of subjects: 51
Study 19368145 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Aloe arborescens (10 ml thrice daily)
Number of subjects: 240
Study 19368145 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 240
Study 19368145 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Aloe arborescens
Number of subjects: 240
Study 16442593 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 every 3-week cycle) and carboplatin (area under the curve of 5 every 3-week cycle)
Number of subjects: 40
Study 16442593 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone (12 mg/m2 every 3-week cycle)
Number of subjects: 40
Study 16442593 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Number of subjects: 40
Study 16442593 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 40
Study 14755192 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane-Propofol
Number of subjects: 46
Study 14755192 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 46
Study 11424018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical resiquimod gel 0.01% (twice or thrice weekly) or 0.05% (once or twice weekly)
Number of subjects: 52
Study 11424018 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 52
Study 11424018 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiquimod-treated patients
Number of subjects: 52
Study 11424018 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-treated patients
Number of subjects: 52
Study 8618466 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy of varying intensities (specific details not provided)
Number of subjects: 1034
Study 8618466 — intervention group
Group type: COMPARATOR
Intervention: Induction treatment (specific details not provided)
Number of subjects: 1034
Study 8618466 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index based on age, LDH, M3 morphology, and karyotype
Number of subjects: 1034
Study 8618466 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 60
Number of subjects: 1034
Study 1533542 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg kg‐1
Number of subjects: 10
Study 1533542 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg kg‐1
Number of subjects: 10
Study 1533542 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 and 12 mg kg‐1
Number of subjects: 10
Study 10268818 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nursing intervention
Number of subjects: 0
Study 10268818 — intervention group
Group type: COMPARATOR
Intervention: Pretest characteristics
Number of subjects: 0
Study 31418422 — intervention group
Group type: EXPERIMENTAL
Intervention: PiP program (tailored web-based parenting intervention)
Number of subjects: 359
Study 31418422 — intervention group
Group type: COMPARATOR
Intervention: Educational factsheets (active control)
Number of subjects: 359
Study 29077637 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 maximal knee flexor eccentric contractions (60MaxEC)
Number of subjects: 39
Study 29077637 — intervention group
Group type: EXPERIMENTAL
Intervention: 60MaxEC at 1 day later
Number of subjects: 39
Study 29077637 — intervention group
Group type: EXPERIMENTAL
Intervention: 60MaxEC at 7 days later
Number of subjects: 39
Study 29077637 — intervention group
Group type: EXPERIMENTAL
Intervention: 60MaxEC at 28 days later
Number of subjects: 39
Study 29077637 — intervention group
Group type: COMPARATOR
Intervention: Control group performing 60MaxEC separated by 14 d
Number of subjects: 39
Study 26921083 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan gum OVB slurry
Number of subjects: 24
Study 26921083 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey OVB slurry
Number of subjects: 24
Study 26921083 — intervention group
Group type: COMPARATOR
Intervention: Sucralose OVB slurry
Number of subjects: 24
Study 25156968 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (40 mg/d)
Number of subjects: 48
Study 25156968 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (2 g/d)
Number of subjects: 48
Study 25156968 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study 25156968 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum glucose concentrations
Number of subjects: 48
Study 25156968 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HOMA-IR
Number of subjects: 48
Study 25156968 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 48
Study 22192409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distraction tasks
Number of subjects: 30
Study 22192409 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 30
Study 22192409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CPM and distraction
Number of subjects: 30
Study 22192409 — intervention group
Group type: COMPARATOR
Intervention: CPM
Number of subjects: 30
Study 22192409 — intervention group
Group type: COMPARATOR
Intervention: Cognitive distraction
Number of subjects: 30
Study 20338728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen administered 60 min preoperatively
Number of subjects: 96
Study 20338728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen administered 60 min postoperatively
Number of subjects: 96
Study 20338728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no ketoprofen)
Number of subjects: 96
Study 18843872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (5 mg) 1-tablet three times daily for three months
Number of subjects: 33
Study 18843872 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1-tablet three times daily for the first month
Number of subjects: 33
Study 16028634 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high vitamin A intake with a liver meal (up to 120,000 IU)
Number of subjects: 0
Study 16028634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling results with literature data
Number of subjects: 0
Study 11842071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO(2 max))
Number of subjects: 24
Study 11842071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (70% VO(2 max))
Number of subjects: 24
Study 11842071 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 24
Study 10365036 — intervention group
Group type: EXPERIMENTAL
Intervention: Topcon ImageNet (TI) system
Number of subjects: 28
Study 10365036 — intervention group
Group type: COMPARATOR
Intervention: Heidelberg retina tomograph (HRT)
Number of subjects: 28
Study 8749165 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear acceleration in a space‐fixed imaginary gaze condition (LSEM)
Number of subjects: 0
Study 8749165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic pursuit of a moving sound source (SSPEM)
Number of subjects: 0
Study 1525750 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Assisted Learning (PAL) prevention program
Number of subjects: 0
Study 3894551 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine medication (one active medication patch)
Number of subjects: 30